Literature DB >> 18604559

Muscle weakness in a girl with autoimmune hepatitis and Graves' disease.

Ahmed Sarkhy1, Rabindranath Persad, Mark Tarnopolsky.   

Abstract

Autoimmune hepatitis (AIH) is a chronic hepatic autoimmune disease of unknown etiology associated with inflammatory changes and autoantibodies. The combination of AIH, Grave's disease, and myasthenia gravis (MG) is rare, with only one other case reported. We report a pediatric patient with AIH type 2 and Grave's disease who developed MG whilst on a treatment with corticosteroids. A 13-year-old girl, diagnosed with thyrotoxicosis, was identified as having AIH type 2. During the course of her therapy, she developed muscle weakness. Investigations revealed increased anti-acetylcholine receptor (AChR) antibodies and her electromyography (EMG) was characteristic for MG. Her course is described here. This case highlights the importance of investigating muscle weakness in severely ill hospitalized patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18604559     DOI: 10.1007/s00431-008-0738-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

1.  Autoimmune hepatitis associated with Graves' disease.

Authors:  Binglin Cui; Masanori Abe; Satoshi Hidata; Seiji Nakanishi; Bunzo Matsuura; Kojiro Michitaka; Kazuhisa Yamamoto; Norio Horiike; Morikazu Onji
Journal:  Intern Med       Date:  2003-04       Impact factor: 1.271

2.  Benefit from alternate-day prednisone in myasthenia gravis.

Authors:  J R Warmolts; W K Engel
Journal:  N Engl J Med       Date:  1972-01-06       Impact factor: 91.245

3.  Meeting report: International Autoimmune Hepatitis Group.

Authors:  P J Johnson; I G McFarlane
Journal:  Hepatology       Date:  1993-10       Impact factor: 17.425

4.  Natural history, clinical features, and treatment of autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Semin Liver Dis       Date:  1984-02       Impact factor: 6.115

5.  Thyrotoxic periodic paralysis in a Hispanic man after the administration of prednisone.

Authors:  Zhao Liu; Lewis E Braverman; Alan Malabanan
Journal:  Endocr Pract       Date:  2006 Jul-Aug       Impact factor: 3.443

6.  The otolaryngologic presentation of myasthenia gravis.

Authors:  R J Carpenter; T J McDonald; F M Howard
Journal:  Laryngoscope       Date:  1979-06       Impact factor: 3.325

7.  Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful?

Authors:  Regan L Ebbeson; Richard A Schreiber
Journal:  Clin Gastroenterol Hepatol       Date:  2004-10       Impact factor: 11.382

8.  A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.

Authors:  J Palace; J Newsom-Davis; B Lecky
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

Review 9.  The validity and importance of subtypes in autoimmune hepatitis: a point of view.

Authors:  A J Czaja; M P Manns
Journal:  Am J Gastroenterol       Date:  1995-08       Impact factor: 10.864

10.  A stronger approach to weakness in the intensive care unit.

Authors:  G Bryan Young; Robert R Hammond
Journal:  Crit Care       Date:  2004-10-01       Impact factor: 9.097

View more
  1 in total

1.  Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course.

Authors:  Justyna Kubiszewska; Beata Szyluk; Piotr Szczudlik; Zbigniew Bartoszewicz; Małgorzata Dutkiewicz; Maksymilian Bielecki; Tomasz Bednarczuk; Anna Kostera-Pruszczyk
Journal:  Brain Behav       Date:  2016-08-04       Impact factor: 2.708

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.